Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: Confirmation of the pharmacokinetic interaction potential of quetiapine

Pharmacopsychiatry

Volumn 41, Issue 6, 2008, Pages 258-259

  Schulz Du Bois, C ^a   Schulz Du Bois, A C ^a   Bewig, B ^a   Gerstner, I ^a   Aldenhoff, J B ^a   Cascorbi, I ^a   Ufer, Mike ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; EZETIMIBE; GLIBENCLAMIDE; METFORMIN; OMEPRAZOLE; QUETIAPINE; SULTAMICILLIN; VALPROIC ACID;

ADULT; ARTICLE; CASE REPORT; CONSCIOUSNESS DISORDER; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG OVERDOSE; DRUG WITHDRAWAL; EVENING DOSAGE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; LOWER RESPIRATORY TRACT INFECTION; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SCHIZOAFFECTIVE PSYCHOSIS; STEADY STATE; SYMPTOM;

ADULT; ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; CLARITHROMYCIN; DIBENZOTHIAZEPINES; DRUG INTERACTIONS; HUMANS; MALE; METABOLIC SYNDROME X; OVERDOSE; PSYCHOTIC DISORDERS;

EID: 58049100409     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1082071     Document Type: Article

References (12)

1. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265
2. Chan WK, Nguyen LT, Miller VP, Harris RZ. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998; 62: 135-142
3. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40: 509-522
4. Frahnert C, Rao ML, Grasmader K. Analysis of eighteen antidepressants, four atypical antipsychotics and active metabolites in serum by liquid chromatography: a simple tool for therapeutic drug monitoring. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 794: 35-47
5. Gerlach M, Hunnerkopf R, Rothenhofer S, Libal G, Burger R, Clement HW et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 2007; 40: 72-76
6. Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Clin Pharmacol 2006; 61: 58-69
7. Hiemke C, Dragicevic A, Grunder G, Hatter S, Sachse J, Vernaleken I et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26: 156-160
8. Pessina A, Turlizzi E, Bonomi A, Guizzardi F, Cavicchim L, Croera C et al. In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Pharmacopsychiatry 2006; 39: 20-22
9. Polasek TM, Miners JO. Quantitative prediction of macrolicle drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pbarmacol 2006; 62: 203-208
10. Quinney SK, Haelmer BD, Rhoades MB, Lin Z, Gorski JC, Hall SD. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol 2008; 65: 98-109
11. Spina E, Leon J de. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100: 4-22
12. Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2000; 24: 521-533